1) 日本産科婦人科学会婦人科腫瘍委員会報告 : 2005年度子宮体癌患者年報.日産婦誌59 : 949─979, 2007
2) Kelley RM, Baker WH : Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 264 : 216─222, 1961
3) Thigpen T, et al : Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma : results of therapy and correlation with estrogen and progesterone receptor levels. The Gynecologic Oncology Group experience. Endocrinology and malignancy. pp446─456, Parthenon Publishers, 1986
4) Rendina GM, Donadio C, Fabri M, et al : Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 4 : 285─291, 1984
5) Lenzs SS, Brady MF, Major FJ, et al : High─dose megestrol acetate in advanced or recurrent endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol 14 : 357─361, 1996
6) Piver MS, Barlow JJ, Lurain JR, et al : Medroxyprogesterone acetate(Depo─Proverra)vs hydroxyprogesterone caproate(Delalutin)in women with metastatic endometrial adenocarcinoma. Cancer 45 : 268─272, 1980
7) Thigpen JT, Brady MF, Alvarez RD, et al : Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma : a dose─response study by the Gynecologic Oncology Group. J Clin Oncol 17 : 1736─1744, 1999
8) Kauppila A : Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. Acta Oncol 28 : 561─566, 1989
9) Lessey BA, Killam AP, Metzger DA, et al : Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab 67 : 334─340, 1988
10) Guidice LC : Growth factors and growth modulators in human uterine endometrium ; their potential relevance to reproductive medicine. Fertil Steril 61 : 1─17, 1994
11) Lecanda J, Parekh TV, Gama P, et al : Transforming growth factor─β, estrogen, progesterone converge on the regulation of p27kip1 in the normal and malignant endometrium. Cancer Res 67 : 1007─1018, 2007
12) Di Nezza LA, Jobling T, Salamonsen LA : Progestin suppresses matrix metalloproteinase production in endometrial cancer. Gynecol Oncol 89 : 325─333, 2003
13) Fujimoto J, Sakaguchi H, Hirose R, et al : Progestins suppress estrogen─induced expression of vascular endothelial growth factor(VEGF)subtypes in uterine endometrial cancer cells. Cancer Lett 141 : 63─71, 1999
14) 泉雄 勝 : 協和発酵の抗悪性腫瘍剤.p44,協和発酵工業株式会社,1989
15) 栗原操寿,他 : 子宮内膜癌に対するMedroxyprogesterone acetate(MPA)の治療効果に関する検討.産婦の実際34 : 517─536,1985
16) 厚生省薬務局安全課 : 乳癌,子宮体癌患者における高用量酢酸メドロキシプロゲステロン投与中の血栓症の発現.医薬品研究23 : 664─671,1992
17) Rose PG, Brunetto VL, VanLe L, et al : A phaseII trial of anastrozole in advanced recurrent or persistent endometrial carcinoma : Gynecologic Oncology Group study. Gynecol Oncol 78 : 212─216, 2000
18) Ma BB, Oza A, Eisenhauser E, et al : The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers ; a study of the National Cancer Institute of Canada Clinical Trial Group. Int J Gynecol Cancer 14 : 650─668, 2004
19) Jeyarajah AR, Gallagher CJ, Blake PR, et al : Long─term follow─up of gonadotrophin─releasing hormone analog treatment for recurrent endometrial cancer. Gynecol Oncol 63 : 47─52, 1996
20) Lhomme C, Fumolean P, Fargeot P, et al : A multicenter phaseII study with triprorelin(sustained─release LHRH agonist)in advanced or recurrent endometrial carcinoma : a French anticancer federation study. Gynecol Oncol 75 : 187─193, 1999
21) Asbury RF, Brunetto VL, Lee RB, et al : Goserelin acetate as treatment for recurrent endometrial carcinoma : a Gynecologic Oncology Group Study. Am J Clin Oncol 25 : 557─560, 2002
22) Grundker C, Schlotawa L, Viereck V, et al : Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH─IIon human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 151 : 141─149, 2004
23) Fister S, Gunthert AR, Emons G, et al : Gonadotropin─releasing hormone typeII antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo. Cancer Res 67 : 1750─1756, 2007
24) Thigpen T, Brandy MF, Homesley HD, et al : Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol 19 : 364─367, 2001
25) Quinn MA, Campbell JJ : Tamoxifen therapy in advanced/recurrent endometrial carcinoma. Gynecol Oncol 32 : 1─3, 1989
26) Whitney CW, Brunetto VL, Zaino RJ, et al : PhaseIIstudy of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma : a Gynecologic Oncology Group study. Gynecol Oncol 92 : 4─9, 2004
27) McMeekin DS, Gordon A, Fowler J, et al : A phaseII trial of arzoxifen, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol 90 : 64─69, 2003
)after prior progestin and anastrozole therapy. Gynecol Oncol 100 : 439─441, 2006
29) Gitsch G, Hanzal E, Jensen D, et al : Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 85 : 504─508, 1995
30) Ushijima K, Yahata H, Yoshikawa H, et al : Multicenter phaseII study of fertility─sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25 : 2798─2803, 2007
31) Yamazawa K, Hirai M, Fujito A, et al : Fertility─preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 22 : 1953─1958, 2007
32) Yahata T, Fujita K, Aoki Y, et al : Long─term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod 21 : 1070─1075, 2006